[1. Goni Lee, Seung Eun Lee, Kyung-Ha Ryu, and Eun Sun Yoo. Posterior reversible encephalopathy syndrome in pediatric patients undergoing treatment for hemophagocytic lymphohistiocytosis: clinical outcomes and putative risk factors. Blood Res. 2013 Dec; 48(4): 258–265. doi: 10.5045/br.2013.48.4.258.10.5045/br.2013.48.4.258389438424466550]Open DOISearch in Google Scholar
[2. Riccardo Masetti, Duccio Maria Cordelli, Daniele Zama, Francesca Vendemini, Carlotta Biagi, Emilio Franzoni, Andrea Pession. PRES in Children Undergoing Hematopoietic Stem Cell or Solid Organ Transplantation. Pediatrics:135(5); 890-902 doi:10.1542/peds.2014-232510.1542/peds.2014-232525917987]Open DOISearch in Google Scholar
[3. D Zama, R Masetti, DM Cordelli, et all. Risk factor analysis of posterior reversible encephalopathy syndrome after allogeneic hematopoietic SCT in children. Bone Marrow Transplantation (2014) 49, 1538–154010.1038/bmt.2014.18225133894]Search in Google Scholar
[4. Javid Gaziev, Simone Marziali, Katia Paciaroni et all. Posterior Reversible Encephalopathy Syndrome after Hematopoietic Cell Transplantation in Children with Hemoglobinopathies. Biology of Blood and Marrow Transplantation Journal, 2017. 23:9;1531-1540. doi: 10.1016/j. bbmt.2017.05.033.10.1016/j.bbmt.2017.05.03328602890]Open DOISearch in Google Scholar
[5. K Straathof, P Anoop, Z Allwood, J Silva, O Nikolajeva, R Chiesa, P Veys, PJ Amrolia and K RaoLong-term outcome following cyclosporine- related neurotoxicity in paediatric allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplantation (2017) 52, 159–162 doi: 10.1038/bmt.2016.232.10.1038/bmt.2016.23227643866522013327643866]Open DOISearch in Google Scholar
[6. Hammerstrom AE, Howell J, Gulbis A, Rondon G, Champlin RE, Popat U. Tacrolimus-associated posterior reversible encephalopathy syndrome in hematopoietic allogeneic stem cell transplantation. Am J Hematol 2013; 88: 301–305. doi: 10.1002/ajh.23402.10.1002/ajh.234022346037823460378]Open DOISearch in Google Scholar
[7. Johnston L, Florek M, Armstrong R, et al. Sirolimus and Mycophenolate Mofetil as Graft-versus- Host Disease Prophylaxis in Myeloablative, Matched Related Donor Hematopoietic Cell Transplantation. Bone marrow transplantation. 2012;47(4):581-588. doi:10.1038/bmt.2011.104.10.1038/bmt.2011.104316305521552302]Open DOISearch in Google Scholar
[8. Noè A, Cappelli B, Biffi A, Chiesa R, Frugnoli I, Biral E et al. High incidence of severe cyclosporine neurotoxicity in children affected by haemoglobinopaties undergoing myeloablative haematopoietic stem cell transplantation: early diagnosis and prompt intervention ameliorates neurological outcome. Ital J Pediatr 2010; 36:14. doi: 10.1186/1824-7288-36-14.10.1186/1824-7288-36-14282957220181110]Search in Google Scholar
[9. Erer B, Polchi P, Lucarelli G, Angelucci E, Baronciani D, Galimberti M et al. CsA-associated neurotoxicity and ineffective prophylaxis with clonazepam in patients transplanted for thalassemia major: analysis of risk factors. Bone Marrow Transplant 1996; 18: 157–162.]Search in Google Scholar
[10. Stübgen J-P. Posterior reversible encephalopathy syndrome (PRES) after granulocyte-colony stimulating factor (G-CSF) therapy: a report of 2 cases. J Neurol Sci 2012; 321: 35–38. doi: 10.1016/j.jns.2012.07.10.1016/j.jns.2012.07.028]Search in Google Scholar